Aethlon Medical Inc

Invention:	Hemofiltration device
Trademark:	Hemopurifier®
Patents:	5
NYSE:	AEMD

The invention

​The Aethlon Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. In cancer, the Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis and inhibit the benefit of leading cancer therapies. The Hemopurifier can be used on the established infrastructure of continuous renal replacement therapy, or CRRT, and dialysis instruments located in hospitals and clinics worldwide

Performance advantage

The performance advantage of the Hemopurifier lies in its ability to clear exosomes that facilitate tumor growth and spread, thus potentially enhancing the efficacy of cancer treatments. Additionally, it demonstrates promise in treating a broad spectrum of life-threatening viruses, underlining its versatility and potential impact in both oncology and infectious diseases.

Intellectual property

Aethlon has a portfolio of over 50 issued patents and pending applications worldwide. The company currently have five issued U.S. patents and 32 issued patents in countries outside of the United States. In addition, the company has thirteen patent applications pending worldwide related to the Hemopurifier product platform and other technologies. 

Regulatory status

The U.S. FDA has designated the Hemopurifier as a "Breakthrough Device" for two indications: the treatment of individuals with advanced or metastatic cancer who are unresponsive or intolerant to standard care, and for life-threatening viruses not addressed with approved therapies.